摘要
约50%的非小细胞肺癌(NSCLC)患者在确诊时已处于晚期,尽管目前的标准治疗已将靶向治疗、免疫治疗和全身化疗纳入其中,但患者的预后仍然充满挑战。研究发现,人滋养层细胞表面抗原2(TROP2)在NSCLC中广泛表达,并与患者不良预后密切相关。本文深入探讨了针对TROP2的新型抗体偶联药物datopotamab deruxtecan(Dato-DXd,DS-1062)在NSCLC治疗中的最新应用进展,详细分析了Dato-DXd的技术设计,通过最新的临床试验数据评估了其疗效及安全性。
Approximately 50%of patients with non-small-cell lung cancer(NSCLC)are diagnosed at advanced stages and face a challenging prognosis despite the integration of targeted therapies,immun-otherapy,and systemic chemotherapy into current standard care.A key factor in this context is trophoblast cell-surface antigen 2(TROP2),which is widely expressed in NSCLC and strongly associated with poor patient outcomes.This article examines the latest developments in the application of datopotamab deruxtecan(Dato-DXd,DS-1062),a novel antibody-drug conjugate targeting TROP2,in the treatment of NSCLC.It provides a detailed assessment of Dato-DXd’s technical design,evaluates its efficacy by using recent clinical trial data,and discusses its safety profile.
作者
陈露露
宋启斌
CHEN Luu;SONG Qibin(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)
出处
《肿瘤防治研究》
CAS
2024年第7期535-541,共7页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金(82102841,82273094)。
